These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39295128)

  • 1. The correlation between serum bone metabolism indexes and bone disease and survival in newly diagnosed multiple myeloma patients.
    Huang L; Zhong Y; Chen Q; He D; Zheng G; Yang Y; Han X; Wu W; Zhao Y; Li Y; Yang L; Cai Z; He J
    Cancer Biol Ther; 2024 Dec; 25(1):2403205. PubMed ID: 39295128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bone Metabolism of Multiple Myeloma Bone Disease Patients with Different Blood Separation Results].
    Fan ZW; Chu NL; Yan S; Qiao JQ; Yu QY; Zhang JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):799-804. PubMed ID: 38926970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG).
    Abildgaard N; Bentzen SM; Nielsen JL; Heickendorff L
    Br J Haematol; 1997 Jan; 96(1):103-10. PubMed ID: 9012695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of the bone turnover markers in multiple myeloma.
    Auzina D; Erts R; Lejniece S
    Exp Oncol; 2017 Mar; 39(1):53-56. PubMed ID: 28361850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis.
    Bao L; Wang YT; Lu MQ; Chu B; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH; Liu X; Zhao X; Wang MZ; Chen Y; Hu WK
    Front Endocrinol (Lausanne); 2023; 14():1157969. PubMed ID: 37181039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chinese bone turnover marker study: reference ranges for C-terminal telopeptide of type I collagen and procollagen I N-terminal peptide by age and gender.
    Li M; Li Y; Deng W; Zhang Z; Deng Z; Hu Y; Xia W; Xu L
    PLoS One; 2014; 9(8):e103841. PubMed ID: 25117452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical characteristics of bone disease in multiple myeloma and clinical significance of monitoring bone metabolic markers].
    Chu B; Lu MQ; Wu MQ; Shi L; Fu LN; Gao S; Fang LJ; Xiang QQ; Bao L
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(18):1424-9. PubMed ID: 27266350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relationship between Bone Markers and the Progression of Multiple Myeloma].
    Liu Y; Ke XY; Tian L; Wan W; Dong F; Wang J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1433-1436. PubMed ID: 27784370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma.
    Kowalska M; Druzd-Sitek A; Fuksiewicz M; Kotowicz B; Chechlinska M; Syczewska M; Walewski J; Kaminska J
    Clin Biochem; 2010 Apr; 43(6):604-8. PubMed ID: 20045402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation between serum HDL/LDL and t-PINP /β-CTX and osteoporotic vertebral fractures in elderly women].
    Sang Y; Zou M; Yue JB
    Zhongguo Gu Shang; 2024 Jun; 37(6):5655-70. PubMed ID: 38910378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical significance of the ratio of serum beta-CTX/PINP in multiple myeloma bone diseases and bone metastases].
    Yang SW; Ma RJ; Zhao JJ; Yuan XL; Jiang L; Yang J; Lei PC; Zhang Y; Zhang L; Liu G; Wang F; Zhu ZM
    Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2583-2587. PubMed ID: 30220144
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios.
    Carlson K; Larsson A; Simonsson B; Turesson I; Westin J; Ljunghall S
    Eur J Haematol; 1999 May; 62(5):300-6. PubMed ID: 10359057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma.
    Ting KR; Brady JJ; Hameed A; Le G; Meiller J; Verburgh E; Bayers C; Benjamin D; Anderson KC; Richardson PG; Dowling P; Clynes M; Fitzgibbon MC; O'Gorman P
    Br J Haematol; 2016 Apr; 173(1):82-8. PubMed ID: 26787413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
    Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
    J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical significance of serum bone metabolic markers in diagnosis and monitoring of myeloma bone disease].
    Peng F; Fu R; Liu H; Wang Y; Ding K; Ding S; Liu Z; Ruan E; Qu W; Wang H; Xing L; Wang X; Wang G; Song J; Wu Y; Li L; Liu H; Guan J; Shao Z
    Zhonghua Yi Xue Za Zhi; 2015 Nov; 95(42):3436-9. PubMed ID: 26813134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological bone markers and joint damage in early polyarthritis.
    Jansen LM; van der Horst-Bruinsma I; Lems WF; van Schaardenburg D; van de Stadt R; de Koning M; Dijkmans BA
    J Rheumatol; 2004 Aug; 31(8):1491-6. PubMed ID: 15290726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of changes in serum high t-PINP/β-CTX ratio and risk of re-fracture after vertebral osteoporotic fracture surgery.
    Lin XB; Ye H; He LJ; Xu ZB
    Eur Rev Med Pharmacol Sci; 2023 Nov; 27(22):10860-10867. PubMed ID: 38039015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Applied Value of Serum Bone Turnover Markers in Patients with Myeloma Bone Disease].
    Wang GZ; Wang ZF; Wang J; Ma L; Zhou L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1618-1624. PubMed ID: 33067963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma.
    Vallet S; Hoyle NR; Kyle RA; Podar K; Pecherstorfer M
    Leuk Lymphoma; 2018 Oct; 59(10):2431-2438. PubMed ID: 29345175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.